Company / Cash per Share
Summit Therapeutics Inc. Cash per Share History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$0.30
FY2025
5-year range
$0.15 / $3.56
FY2021-FY2025
Trend
+101.6%
vs FY2024
Sector context
#188 of 205
Health Care
What the data says
Among 205 Health Care companies, Summit Therapeutics Inc. is in the bottom 8% for cash per share. Cash per Share returned to growth in FY2025 after 2 years of decline, reaching $0.30.
Based on SEC 10-K filings.
0.30 in FY2025 with a 5-year CAGR of -21.2%.
Declined from $0.34 to $0.30 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- -56.1%
- 5-Year CAGR
- -21.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 205This company $0.30 Sector average $72.93
▼
-99.6% below sector average
Key checks
Key Insights
- In FY2025, cash per share increased 101.6% year-over-year.
- Ranks #188 out of 205 companies in the Health Care sector.
- Peak cash per share was recorded in FY2022.
- Lowest cash per share in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.30 | +101.6% |
| FY2024 | $0.15 | -55.8% |
| FY2023 | $0.34 | -90.5% |
| FY2022 | $3.56 | +1565.0% |
| FY2021 | $0.21 | -78.4% |
| FY2020 | $0.99 | -49.2% |
| FY2019 | $1.94 | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026